Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
We does not use any cookie based Analytics or tracking on our websites; see details here.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
12 August 2020
CMS advised global private equity firm Advent International and its European medicines producer Zentiva on the acquisition of the CEE business of global generic and OTC pharmaceuticals manufacturer Alvogen, which has now been named CEE Deal of the Year.
The Deal of the Year transaction brought together two leading branded generics and over-the counter businesses in the CEE region and involved the cooperation of more than 80 lawyers based across the Czech Republic, Russia, Romania, Bulgaria, Hungary, Poland, UK, Netherlands and the Balkans.
The CMS team that supported Zentiva from Russia included:
Life Sciences and Healthcare: Vsevolod Tyupa and Alexey Shadrin;
Corporate: Dmitry Bogdanov, Elizaveta Rakova;
Competition and Antitrust: Elena Andrianova, Timur Sadvakasov, Maria Ermolaeva;
Commercial and Employment: Maxim Gubanov, Irina Skvortsova, Anastasia Entyakova;
Tax: Igor Ershov, Maria Kabanova.
CEE Legal Matters’ Deal of the Year Awards, one of the most prestigious peer-selected legal awards, recognise the most important transactions in Central and Eastern Europe across the year.
Read more about the CEE Legal Matters’ Deal of the Year Awards in 2019.